| ★ |  What is the added value of triple therapy in lupus nephritis? | | 438 | — | |
| 2 |  Hydroxychloroquine in connective tissue diseases: benefits and controversial aspects | | 1.8K | — | 80 |
| 7 |  IgG4-related disease (IgG4-RD): update on diagnosis and treatments in 2025 | | 1.3K | — | 77 |
| 16 |  From basics to updates for cutaneous lupus erythematosus (CLE) | | 1.1K | — | 75 |
| 5 |  Recent advances in the treatment of inflammatory myopathies | | 618 | — | 77 |
| 11 |  Steroids in Relapsing Polychondritis | | 474 | — | 76 |
| 1 |  CAR-T Therapy in Systemic Lupus Erythematosus (SLE): Explained to the Patient | | 441 | — | 82 |
| 8 |  Quality of life in Relapsing Polychondritis (RP) | | 412 | — | 76 |
| 10 |  Kidney involvement in Sjögren’s Disease (SjD) | | 401 | — | 76 |
| 14 |  Why morning joint stiffness and swelling in rheumatic diseases? | | 398 | — | 76 |
| 4 |  Update on B cell targeting therapies in IgG4-related disease | | 375 | — | 78 |
| 13 |  Treatment of systemic sclerosis-associated interstitial lung disease: where do we stand in 2025? | | 285 | — | 76 |
| 15 |  Thrombocytopenia in systemic lupus erythematosus (SLE) | | 249 | — | 75 |
| 12 |  Exercise as a non-pharmacological treatment adjunct to pharmacotherapy in systemic sclerosis. | | 222 | — | 76 |
| 18 |  Exercise in adult idiopathic inflammatory myopathies (IIMs) | | 188 | — | 74 |
| 17 |  The transition from benign to secondary Raynaud’s phenomenon | | 186 | — | 74 |
| 6 |  The Path to Better Treatments: A Patient-Friendly Guide to Sjögren’s Clinical Trials | | 171 | — | 77 |
| 19 |  Imaging in Relapsing Polychondritis (RP) | | 171 | — | 74 |
| 20 |  Unconventional therapies in connective tissue diseases | | 110 | — | 73 |
| 9 |  Osteoporosis in rare and complex connective tissue diseases | | 96 | — | 76 |
| 3 |  Screening and treatment of systemic sclerosis-associated PAH: where do we stand in 2024? | | 53 | — | 80 |